Germany· DE-A57-188036b4351c641a
Jutussin S R 9
A medicinal product containing atropa belladonna dil. d4, bryonia dil. d3, cuprum aceticum dil. d12, drosera dil. d4, sticta dil. d4, registered in Germany by Pharmazeutische Fabrik Dr. Reckeweg & Co. Gmbh.
Checked against EMA Article 57 (European Union) on
Informational only — not a medical device.
The record
At a glance
EMA Article 57 (European Union)- Active substance
- Atropa Belladonna Dil. D4, Bryonia Dil. D3, Cuprum Aceticum Dil. D12, Drosera Dil. D4, Sticta Dil. D4
- Manufacturer
- Pharmazeutische Fabrik Dr. Reckeweg & Co. Gmbh
- Country
- Germany (DE)
- ATC code
- —
- Reimbursed
- Not published by this register
- Source register
- EMA Article 57 (European Union)
- Last checked
- September 30, 2026
Packs & prices · 0
No packs listed by the register for this record.
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of EMA Article 57 (European Union). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/e9318cef-4c5d-47d9-88c5-0f52abfb4b75 GET /v1/drugs/e9318cef-4c5d-47d9-88c5-0f52abfb4b75?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"pzn": null,
"route": "Oral Use",
"source": "ema_art57_de",
"ma_number": null,
"substance": "Atropa Belladonna Dil. D4, Bryonia Dil. D3, Cuprum Aceticum Dil. D12, Drosera Dil. D4, Sticta Dil. D4",
"atc_from_source": null,
"authorisation_country": "Germany"
}See everything about atropa belladonna dil. d4, bryonia dil. d3, cuprum aceticum dil. d12, drosera dil. d4, sticta dil. d4.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.